Pfizer (NYSE:PFE) Trading Up 0.4% - Should You Buy?

Pfizer Inc. (NYSE:PFE - Get Free Report) was up 0.4% during trading on Wednesday . The stock traded as high as $23.06 and last traded at $22.63. Approximately 18,637,140 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 40,372,067 shares. The stock had previously closed at $22.53.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PFE. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday. They set a "neutral" rating and a $24.00 target price on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $29.57.

Pfizer Trading Down 0.8 %

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business's 50-day moving average price is $24.75 and its 200 day moving average price is $26.08. The company has a market cap of $126.81 billion, a P/E ratio of 15.86, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Nordea Investment Management AB grew its position in Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI increased its position in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after purchasing an additional 159,984 shares in the last quarter. Copley Financial Group Inc. bought a new position in Pfizer in the 3rd quarter valued at approximately $577,000. Mcdonald Partners LLC grew its stake in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after buying an additional 9,963 shares during the last quarter. Finally, Merit Financial Group LLC increased its holdings in shares of Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock worth $3,395,000 after buying an additional 48,397 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.